Graham G. Walmsley
- SEC CIK
- 0001777517
No open-market purchases or sales filed in the past year.
Current role at each company
- OLMA Olema Pharmaceuticals, Inc.Directoras of Jun 23, 2026
- AKRO Akero Therapeutics, Inc.Directoras of Dec 9, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Graham G. Walmsley as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
AKRO Akero Therapeutics, Inc.
Director7 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2023 (view filing) | Sep 19, 2022-May 19, 2023 | 269 days | Graham G. WalmsleyDirector | PPurchase | +520.0K | $29.69 | +$15.4M | New position520.0K after | Amended2 lots |
| Aug 1, 2023 (view filing) | Jul 28-Aug 1 | 4 days | Graham G. WalmsleyDirector | PPurchase | +55.0K | $42.95 | +$2.36M | +10.6%575.0K after | 2 lots |
| Aug 10, 2023 (view filing) | Aug 8 | 2 days | Graham G. WalmsleyDirector | PPurchase | +25.0K | $42.06 | +$1.05M | +4.3%600.0K after | |
| Dec 5, 2023 (view filing) | Nov 30-Dec 1 | 5 daysLate | Graham G. WalmsleyDirector | PPurchase | +100.0K | $16.95 | +$1.69M | +16.7%700.0K after | 2 lots |
| Dec 11, 2023 (view filing) | Dec 8 | 3 days | Graham G. WalmsleyDirector | PPurchase | +100.0K | $19.83 | +$1.98M | +14.3%800.0K after | 2 lots |
| Feb 7, 2025 (view filing) | Jan 30 | 8 daysLate | Graham G. WalmsleyDirector | PPurchase | +200.0K | $48.00 | +$9.60M | +25.0%1.00M after | |
| Mar 27, 2025 (view filing) | Mar 25-27 | 2 days | Graham G. WalmsleyDirector | PPurchase | +200.0K | $43.94 | +$8.79M | +20.0%1.20M after | 3 lots |
OLMA Olema Pharmaceuticals, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2023 (view filing) | Sep 12-Dec 5 | 97 daysLate | Graham G. WalmsleyDirector | PPurchase | +640.0K | $10.74 | +$6.87M | +55.2%1.80M after | 4 lots |
| Nov 26, 2024 (view filing) | Jun 4 | 175 days | Graham G. WalmsleyDirector | SSale | −1.18M | $14.85 | −$17.4M | −62.4%708.1K after | Amended2 lots |
| Dec 18, 2024 (view filing) | Dec 13 | 5 days | Graham G. WalmsleyDirector | SSale | −700.8K | $6.75 | −$4.73M | −100.0%0 after | From original |
| Dec 18, 2024 (view filing) | Dec 13 | 5 days | Graham G. WalmsleyDirector | PPurchase | +700.8K | $6.75 | +$4.73M | New position700.8K after | From original |